Asian Pacific Journal of Cancer Prevention

  • 제15권22호
  • /
  • Pages.9643-9647
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Updated Meta-analysis on HER2 Polymorphisms and Risk of Breast Cancer: Evidence from 32 Studies

  • Chen, Wei (Faculty of Environmental Science and Engineering, Kunming University of Science and Technology) ;
  • Yang, Heng (Yunnan Tropical and Subtropical Animal Virus Diseases Laboratory, Yunnan Animal Science and Veterinary Institute) ;
  • Tang, Wen-Ru (Faculty of Medicine, Kunming University of Science and Technology) ;
  • Feng, Shi-Jun (Faculty of Medicine, Kunming University of Science and Technology) ;
  • Wei, Yun-Lin (Faculty of Life Science and Technology, Kunming University of Science and Technology)
  • 발행 : 2014.12.18
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Several studies have been performed to investigate the association of the HER2 Ile655Val polymorphism and breast cancer risk. However, the results were inconsistent. To understand the precise relationship, a meta-analysis was here conducted. Materials and Methods: A search of PubMed conducted to investigate links between the HER2 Ile655Val polymorphism and breast cancer, identified a total of 32 studies, of which 29, including 14,926 cases and 15,768 controls, with odds ratios (ORs) with 95% confidence intervals were used to assess any association. Results: In the overall analysis, the HER2 Ile655Val polymorphism was associated with breast cancer in an additive genetic model (OR=1.136, 95% CI 1.043-1.239, p=0.004) and in a dominant genetic (OR=1.118, 95% CI 1.020-1.227, p=0.018), while no association was found in a recessive genetic model. On subgroup analysis, an association with breast cancer was noted in the additive genetic model (OR=1.111, 95% CI: 1.004-1.230, p=0.042) for the Caucasian subgroup. No significant associations were observed in Asians and Africans in any of the genetic models. Conclusions: In summary, our meta-analysis findings suggest that the HER2 Ile655Val polymorphism is marginally associated with breast cancer susceptibility in worldwide populations with additive and dominant models, but not a recessive model.

키워드

참고문헌

  1. AbdRaboh NR, Shehata HH, Ahmed MB, et al (2013). HER1 R497K and HER2 I655V polymorphisms are linked to development of breast cancer. Dis Markers, 34, 407-17. https://doi.org/10.1155/2013/587682
  2. Akisik E, Dalay N (2004). Estrigen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol, 76, 260-3. https://doi.org/10.1016/j.yexmp.2003.12.005
  3. An HJ, Kim NK, Oh D, et al (2005). Her2V655 genotype and breast cancer progression in Korean women. Pathol Int, 55, 48-52. https://doi.org/10.1111/j.1440-1827.2005.01789.x
  4. Benusiglio PR, Pharoah PD, Smith PL, et al (2006). HapMapbased study of the 17p21 ERBB2 amplicon in susceptibility to breast cancer. Br J Cancer, 95, 1689-95. https://doi.org/10.1038/sj.bjc.6603473
  5. Cooke T, Reeves J, Lanigan A, et al (2001). HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol, 12, 23-8.
  6. Cox DG, Hanknson SE, Hunter DJ (2005). The ERBB2/HER2/ neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenet Genom, 15, 447-50. https://doi.org/10.1097/01.fpc.0000166822.66754.c6
  7. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  8. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-anaysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  9. Fleishman SJ, Schlessinger J, Ben-Tal N (2002). A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA, 99, 15937-40. https://doi.org/10.1073/pnas.252640799
  10. Frank B, Hemminki K, Wirtenberger M, et al (2005). The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis, 26, 643-7.
  11. Kalemi TG, Lambropoulos AF, Gueorguiev M, et al (2005). The association of P53 mutations and P53 codon 72, Her2 codon 655 and MTHFE C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett, 222, 57-65. https://doi.org/10.1016/j.canlet.2004.11.025
  12. Kallel I, Kharrat N, Al-fadhly S, et al (2010). HER2 polymorphisms and breast cancer in Tunisian women. Genet Test Mol Bioma, 14, 29-35. https://doi.org/10.1089/gtmb.2009.0069
  13. Kamali-Sarvestani E, Talei AR, Merat A (2004). Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Cancer Lett, 215, 83-7. https://doi.org/10.1016/j.canlet.2004.04.007
  14. Kara N, Karakus N, Ulusoy AN, et al (2010). P53 codon 72 and HER2 codon 655 polymorphisms in turkish breast cancer patients. DNA Cell Biol, 29, 387-92. https://doi.org/10.1089/dna.2009.0995
  15. Keshava C, McCanlies EC, Keshaca N, et al (2001). Distribution of HER2 (V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett, 173, 37-41. https://doi.org/10.1016/S0304-3835(01)00671-1
  16. Lee SC, Hou MF, Hsieh PC, et al (2008). A case-control study of the HER2 Ile655val polymorphism and risk of breast cancer in Taiwan. Clin Biochem, 41, 121-5. https://doi.org/10.1016/j.clinbiochem.2007.11.005
  17. Lemieux J, Diorio C, Cote MA, et al (2013). Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res, 33, 2569-76.
  18. Linos E, Rosner BA, Linos K (2008). Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J Natl Cancer I, 100, 1352-9. https://doi.org/10.1093/jnci/djn305
  19. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  20. Marie-Genica C (2010). Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Tr, 120, 726-36.
  21. Millikan R, Eaton A, Worley K, et al (2003). HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Tr, 79, 355-64. https://doi.org/10.1023/A:1024068525763
  22. Montgomery KG, Gertig DM, baxter SW, et al (2003). The HER2 I665V polymorphism and risk of breast cancer in women
  23. Mutluhan H, Akbas E, Erdogan NE, et al (2008). The influence of HER2 genotypes as molecular markers on breast cancer outcome. DNA Cell Biol, 27, 575-9. https://doi.org/10.1089/dna.2007.0702
  24. Nakajima M, Sawada H, Yamada Y, et al (1999). The prognostic significance of amplification and overexpression of c-met and c-erB-2 in human gastric carcinomas. Cancer, 85, 1894-902. https://doi.org/10.1002/(SICI)1097-0142(19990501)85:9<1894::AID-CNCR3>3.0.CO;2-J
  25. Naidu R, Yip CH, Taib NA (2008). Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. Neoplasma, 55, 87-95.
  26. Nelson SE, Gould MN, Hampton JM, et al (2005). A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res, 7, 357-64. https://doi.org/10.1186/bcr1004
  27. Ozturk O, Canbay E, Kahraman OT, et al (2013). HER2 Ile655Val and PTEN IVS4 polymorphisms in patients with breast cancer. Mol Biol Rep, 40, 1813-8. https://doi.org/10.1007/s11033-012-2235-2
  28. Papadopoulou E, Simoupoulos K, Tripsianis G, et al (2007). Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer. Neoplasma, 54, 365-73.
  29. Papewalis J, Nikitin AY, Rajewsky MF (1991). G to A polymorphism at amino acid codon 655 of the human erbB-2/ HER2 gene. Nucleic Acids Res, 19, 5452.
  30. Pinto D, Vasconcelos A, Costa S, et al (2004). HER2 polymorphism and breast cancer risk in Portugal. Eur J Cancer Prev, 13, 177-81. https://doi.org/10.1097/01.cej.0000130015.91525.c7
  31. Qu s, Cai Q, Gao YT, et al (2008). ERBB2 genetic polymorphism and breast cancer risk in Chinese women: A population-based case-control study. Breast cancer Res Tr, 110, 169-76. https://doi.org/10.1007/s10549-007-9691-8
  32. Roca L, Dieras V, Roche H, et al (2013). Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial. Breast Cancer Res Tr, 139, 789-800. https://doi.org/10.1007/s10549-013-2587-x
  33. Ross JS, Fletcher JA, Linette GP, et al (2003). The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist, 8, 307-25. https://doi.org/10.1634/theoncologist.8-4-307
  34. Siegel R, Naishadam D, Jemal A (2012). Cancer statistics. CACancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  35. Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74. https://doi.org/10.1073/pnas.191367098
  36. Takano K, Ogasahara K, Kaneda H, et al (1995). Contribution of hydrophobic residues to the stability of human lysozyme: Calormetric studies and X-ray structural analysis of the five isoleucine to valine. J Mol Biol, 254, 62-76. https://doi.org/10.1006/jmbi.1995.0599
  37. Tao WY, Wang CY, Han R, et al (2009). Her2 condon 655 Polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Tr, 114, 371-6. https://doi.org/10.1007/s10549-008-0010-9
  38. Tommasi S, Fedele V, Lacalamita R, et al (2004). Molecular and functional characteristics of erbB2 in normal and cancer breast cells. Cancer Lett, 209, 215-22. https://doi.org/10.1016/j.canlet.2003.12.014
  39. Tommasi S, Fedele V, Lacalamita R, et al (2007). 655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCAL alterations. Cell Oncol, 29, 241-8.
  40. Uzan C, Darai E, Valent A, et al (2009). Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma. Virchows Arch, 454, 525-9. https://doi.org/10.1007/s00428-009-0755-5
  41. Wang HW, Liu LT, Lang ZF, et al (2013). Polymorphisms of ERBB2 and breast cancer risk: a meta-analysis of 26 studies involving 35,088 subjects. J Surg Oncol, 108, 335-6. https://doi.org/10.1002/jso.23404
  42. Xie D, Shu XQ, Deng ZL, et al (2000). Population-based, casecontrol study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst, 92, 412-17. https://doi.org/10.1093/jnci/92.5.412
  43. Zhang M, Guo LL, Cheng Z, et al (2011). A functional polymorphism of TGFBR2 is associated with risk of breast cancer with ER+, PR+, ER+PR+ and HER2- expression in women. Oncol Lett, 2, 653-8.
  44. Ziegler RG, Anderson WF, Gail MH (2008). Increasing breast cancer incidence in China: the numbers add up. J Natl Cancer I, 100, 1339-41. https://doi.org/10.1093/jnci/djn330
  45. Zubor P, Vojvodova A, Danko J, et al (2006). HER-2 [Ile655Val] polymorphism in association with breast cancer risk: A population-based case-control study in Slovakia. Neoplasma, 53, 49-55.

피인용 문헌

  1. Could the Breast Prognostic Biomarker Status Change During Disease Progression? An Immunohistochemical Comparison between Primary Tumors and Synchronous Nodal Metastasis vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4317
  2. Predictive and Prognostic Significance of p27, Akt, PTEN and PI3K Expression in HER2-Positive Metastatic Breast Cancer vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2645
  3. Analysis of different HER-2 mutations in breast cancer progression and drug resistance vol.19, pp.12, 2015, https://doi.org/10.1111/jcmm.12662
  4. Association of BRCA1, BRCA2, RAD51, and HER2 gene polymorphisms with the breast cancer risk in the Bangladeshi population vol.24, pp.2, 2017, https://doi.org/10.1007/s12282-016-0692-5
  5. The Connection of Polymorphisms–238A/G TNF and Ile655Val HER2 Influences the Risk and Molecular Features of Breast Cancer vol.32, pp.3, 2017, https://doi.org/10.3103/S0891416817030053
  6. The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies vol.13, pp.1, 2018, https://doi.org/10.1371/journal.pone.0191972
  7. Her2 Ile655Val polymorphism and its association with breast cancer risk: an updated meta-analysis of case-control studies vol.8, pp.1, 2018, https://doi.org/10.1038/s41598-018-25769-y